Provided herein are fluorophore compounds including rhodol and rhodamine compounds which can be used as fluorescent labels and/or fluorogenic probes and methods of making same. Provided also herein are methods that can be used to track, measure, detect, or screen biological species such as protein, DNA, enzyme, antibody, organelle, cell, tissue, drug, hormone, nucleotide, nucleic acid, polysaccharide or lipid in living organisms. Specifically, the methods include the steps of contacting any of the fluorophore compounds, rhodol compounds and rhodamine compounds disclosed herein with the biological species to form one or more fluorescent compounds, and measuring fluorescence properties of the fluorescent compounds. Provided also herein are high-throughput screening fluorescent methods for detecting or screening biological species.
[EN] CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION<br/>[FR] AGENTS D'ARN CONJUGUÉS À DES GLUCIDES ET LEUR PROCÉDÉ DE PRÉPARATION
申请人:ALNYLAM PHARMACEUTICALS INC
公开号:WO2014025805A1
公开(公告)日:2014-02-13
This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents.
“Bulky-Yet-Flexible” α-Diimine Palladium-Catalyzed Reductive Heck Cross-Coupling: Highly Anti-Markovnikov-Selective Hydroarylation of Alkene in Air
作者:Xu-Wen Yang、Dong-Hui Li、A-Xiang Song、Feng-Shou Liu
DOI:10.1021/acs.joc.0c01509
日期:2020.9.18
regioselective and efficient reductive Heck reaction, a series of moisture- and air-stable α-diimine palladium precatalysts were rationally designed, readily synthesized, and fully characterized. The relationship between the structures of the palladiumcomplexes and the catalytic properties was investigated. It was revealed that the“bulky-yet-flexible”palladiumcomplexes allowed highly anti-Markovnikov-selective
[EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
申请人:ENANTA PHARM INC
公开号:WO2019067864A1
公开(公告)日:2019-04-04
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
MACROCYCLIC, PYRIDAZINONE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS
申请人:Moore Joel D.
公开号:US20090123425A1
公开(公告)日:2009-05-14
The present invention relates to compounds of Formula I, II, or III, or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.